Literature DB >> 31793004

Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.

Guohua An1.   

Abstract

Target-mediated drug disposition (TMDD) is a term to describe a nonlinear pharmacokinetic (PK) phenomenon that is caused by high-affinity binding of a compound to its pharmacologic targets. As the interaction between a drug and its pharmacologic target belongs to the process of pharmacodynamics (PD), TMDD can be viewed as a consequence of "PD affecting PK." Although there are numerous TMDD-related articles in the literature, most of them focus on characterizing TMDD using various mathematical models, which may not be suitable for those readers who have little interest in mathematical modeling and only want to have an understanding of the basic concept. The goal of this review is to serve as a "primer" on TMDD. This review explains (1) how TMDD happens; (2) why large-molecule and small-molecule compounds exhibiting TMDD demonstrate substantially different nonlinear PK behaviors; (3) what nonlinear PK profiles look like in large-molecule and small-molecule compounds exhibiting TMDD, using pegfilgrastim, erythropoietin, ABT-384, and linagliptin as case examples; and (4) how to identify whether the nonlinear PK of a compound is because of TMDD.
© 2019, The American College of Clinical Pharmacology.

Entities:  

Keywords:  ABT-384; Target-mediated drug disposition; erythropoietin; linagliptin; nonlinear PK; pegfilgrastim

Mesh:

Substances:

Year:  2019        PMID: 31793004      PMCID: PMC7472685          DOI: 10.1002/jcph.1545

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  47 in total

1.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model.

Authors:  R J Francis; A N Brown; L Kler; T Fasanella d'Amore; J Nussberger; B Waeber; H R Brunner
Journal:  J Cardiovasc Pharmacol       Date:  1987-01       Impact factor: 3.105

Review 3.  Importance of target-mediated drug disposition for small molecules.

Authors:  Dennis A Smith; Robert A B van Waterschoot; Neil J Parrott; Andrés Olivares-Morales; Thierry Lavé; Malcolm Rowland
Journal:  Drug Discov Today       Date:  2018-06-19       Impact factor: 7.851

4.  Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens.

Authors:  Guohua An; Wei Liu; David A Katz; Gerard J Marek; Walid Awni; Sandeep Dutta
Journal:  Biopharm Drug Dispos       Date:  2014-08-30       Impact factor: 1.627

5.  Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  Donald E Mager; Wojciech Krzyzanski
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

6.  Nonlinear pharmacokinetics of recombinant human macrophage colony-stimulating factor (M-CSF) in rats.

Authors:  R J Bauer; J A Gibbons; D P Bell; Z P Luo; J D Young
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

7.  Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers.

Authors:  A E Till; H J Gomez; M Hichens; J A Bolognese; W R McNabb; B A Brooks; F Noormohamed; A F Lant
Journal:  Biopharm Drug Dispos       Date:  1984 Jul-Sep       Impact factor: 1.627

8.  Change in erythropoietin pharmacokinetics following hematopoietic transplantation.

Authors:  J A Widness; R L Schmidt; R J Hohl; F D Goldman; N H Al-Huniti; K J Freise; P Veng-Pedersen
Journal:  Clin Pharmacol Ther       Date:  2007-04-11       Impact factor: 6.875

9.  Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.

Authors:  Lambertus A Peletier; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-01       Impact factor: 2.745

10.  A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.

Authors:  P Dua; E Hawkins; P H van der Graaf
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-15
View more
  16 in total

1.  A long-acting C-natriuretic peptide for achondroplasia.

Authors:  Eric L Schneider; Christopher W Carreras; Ralph Reid; Gary W Ashley; Daniel V Santi
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-18       Impact factor: 12.779

2.  A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults.

Authors:  Suping Niu; Min Chen; Diqin Yan; Xiangxing Liu; Shuren Guo; Lun Ou; Huaying Fan; Jie Lv; Qian Wang; Wenliang Dong; Lin Xia; Simin Wang; Gang Liu; Qun Gu; Danjie Guo; Hongxia Liu; Huiying Rao; Qingshan Zheng; Xiaoyan Nie; Haifeng Song; Yi Fang
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

3.  Target-mediated exposure enhancement: a previously unexplored limit of TMDD.

Authors:  Patrick M Glassman; Vladimir R Muzykantov
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-06-02       Impact factor: 2.745

4.  Simultaneous Target-Mediated Drug Disposition Model for Two Small-Molecule Compounds Competing for Their Pharmacological Target: Soluble Epoxide Hydrolase.

Authors:  Nan Wu; Bruce D Hammock; Kin Sing Stephen Lee; Guohua An
Journal:  J Pharmacol Exp Ther       Date:  2020-04-01       Impact factor: 4.030

5.  Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Niurys de Castro-Suárez; Mirjam N Trame; Mayra Ramos-Suzarte; José M Dávalos; Raymed A Bacallao-Mendez; Anaelys R Maceo-Sinabele; Víctor Mangas-Sanjuán; Gledys Reynaldo-Fernández; Leyanis Rodríguez-Vera
Journal:  Pharmaceutics       Date:  2020-11-26       Impact factor: 6.321

Review 6.  Target-Mediated Drug Disposition-A Class Effect of Soluble Epoxide Hydrolase Inhibitors.

Authors:  Guohua An; Kin Sing Stephen Lee; Jun Yang; Bruce D Hammock
Journal:  J Clin Pharmacol       Date:  2020-10-19       Impact factor: 3.126

7.  Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects.

Authors:  Yasuhiro Tsuda; Christine Grimaldi; Fenglei Huang; Ewald Benediktus; Nobutaka Yagi; Steven J Padula; In-Jin Jang; Jürgen Steffgen
Journal:  Br J Clin Pharmacol       Date:  2020-12-09       Impact factor: 4.335

8.  Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease.

Authors:  Brian T Welsh; Shaun M Cote; Deborah Meshulam; Justin Jackson; Ajai Pal; Janice Lansita; Ashish Kalra
Journal:  Int J Toxicol       Date:  2021 Jul-Aug       Impact factor: 2.380

9.  Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent.

Authors:  Ashley Nguyen; Diana S-L Chow; Lei Wu; Yang Angela Teng; Mahua Sarkar; Elizabeth G Toups; James S Harrop; Karl M Schmitt; Michele M Johnson; James D Guest; Bizhan Aarabi; Christopher I Shaffrey; Maxwell Boakye; Ralph F Frankowski; Michael G Fehlings; Robert G Grossman
Journal:  J Clin Pharmacol       Date:  2021-07-09       Impact factor: 3.126

10.  A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.

Authors:  Tae Kyu Chung; Hyun A Lee; Sang-In Park; Do-Youn Oh; Keun-Wook Lee; Jin Won Kim; Jee Hyun Kim; Ahmi Woo; Su Jin Lee; Yung-Jue Bang; Howard Lee
Journal:  Clin Transl Sci       Date:  2021-01-25       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.